サイトマップ
・HOME
・概要
・研究内容
・概要
・詳細
・1. ヒトiPS細胞から肝臓細胞等への分化制御に関する分子生物学的解析と創薬研究への応用
・2. 新規遺伝子導入・発現制御技術の開発と遺伝子治療、再生医療、ワクチン等への応用
・3. ノンコーディングRNA（マイクロRNA等）の機能解析と核酸医薬開発への応用
・4. ゲノム編集技術の開発と遺伝子治療、幹細胞研究への応用
Yamaguchi, T., Kawabata, K., Kouyama, E., Ishii, K. J., Katayama, K., Suzuki, T., Kurachi, S., Sakurai, F., Akira, S., and Mizuguchi, H. Induction of type I interferon by adenovirus-encoded small RNAs. Proc. Natl. Acad. Sci. USA, 107, 17286-17291 (2010)
Sakurai, F., Nakashima, K., Yamaguchi, T., Ichinose, T., Kawabata, K., Hayakawa, T., and Mizuguchi, H. Adenovirus serotype 35 vector-induced innate immune responses in dendritic cells derived from wild-type and human CD46-transgenic mice: Comparison with a fiber-substituted Ad vector containing fiber proteins of Ad serotype 35. J. Control. Rel., 148, 212-218 (2010)
Tashiro K., Kawabata K., Inamura M., Takayama K., Furukawa N., Sakurai F., Katayama K., Hayakawa H., Furue-Kusuda M., Mizuguchi H., Adenovirus vector-mediated efficient transduction into human embryonic and induced pluripotent stem cells. Cell Reprogram., 12, 501-507 (2010)
Eto Y., Yoshioka Y., Ishida T., Yao X., Morishige T., Narimatsu S., Mizuguchi H., Mukai Y., Okada N., Kiwada H., Nakagawa S. Optimized PEGylated adenovirus vector reduces the anti-vector humoral immune response against adenovirus and induces a therapeutic effect against metastatic lung cancer. Biol. Pharm. Bull., 33, 1540-1544 (2010)
Ushitora M., Sakurai F., Yamaguchi T., Nakamura S-I., Kondoh M., Yagi K., Kawabata K., Mizuguchi H. Prevention of hepatic ischemia-reperfusion injury by pre-administration of catalase-expressing adenovirus vectors. J. Control. Rel., 142, 431-437 (2010)
Watanabe Y., Kojima T., Kagawa S., Uno F., Hashimoto Y., Kyo S., Mizuguchi H., Tanaka N., Kawamura H., Ichimaru D., Urata Y., Fujiwara T. A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy. Oncogene, 29, 1145-1154 (2010)
Van Geer M.A., Brevoord D., Kuhlmann K.F., Bakker C.T., Mizuguchi H., Wesseling J.G., Ten Kate F.J., Gouma D.J., Oude Elferink R.P., Bosma P.J. A fiber modified adenovirus vector that targets to the EphrinA2 receptor reveals enhanced gene transfer to ex vivo pancreatic cancer. Int. J. Oncol., 36, 233-44 (2010)
Morishige T., Yoshioka Y., Tanabe A., Yao X., Mizuguchi H., Tsunoda S., Tsutsumi Y., Mukai Y., Okada N., Nakagawa S. Comparison of the anti-tumor activity of native, secreted, and membrane-bound LIGHT in mouse tumor models. Int. Immunopharmacol., 10, 26-33 (2010)
Kojima T., Watanabe Y., Hashimoto Y., Kuroda S., Yamasaki Y., Yano S., Ouchi M., Tazawa H., Uno F., Kagawa S., Kyo S., Mizuguchi H., Urata Y., Tanaka N., Fujiwara T. In vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy. Ann. Surg., 251, 1079-1086 (2010)
Akita H., Enoto K., Masuda T., Mizuguchi H., Tani T., Harashima H., Particle tracking of intracellular trafficking of octaarginine-modified liposomes: a comparative study with adenovirus. Mol. Ther., 18, 955-964 (2010)
Yashima S., Yoshizaki S., Shinoda K., Yoshida A., Kondo A., Mizuguchi H., Ryo A., Okuda K., Shimada M. Co-administration of viral vector-based vaccines suppresses antigen-specific effector CD8 T cells. Vaccine, 28, 3257-3264 (2010)
Kakutani H., Kondoh M., Saeki R., Fujii M., Watanabe Y., Mizuguchi H., Yagi K. Claudin-4-targeting of diphtheria toxin fragment A using a C-terminal fragment of Clostridium perfringens enterotoxin. Eur. J. Pharm. Biopharm., 75, 213-217 (2010)
Yao X., Yoshioka Y., Morishige T., Eto Y., Narimatsu S., Mizuguchi H., Mukai Y., Okada N., Nakagawa S. Adenovirus vector covalently conjugated to polyethylene glycol with a cancer-specific promoter suppresses the tumor growth through systemic administration. Biol. Pharm. Bull., 35, 1073-1076 (2010)
櫻井文教、水口裕之；マイクロRNAによる遺伝子発現制御システムを搭載した遺伝子組換えアデノウイルスの開発 、薬学雑誌、130、1497-1504 (2010)
川端健二、田代克久、水口裕之；iPS細胞への遺伝子導入を用いた分化誘導の最適化 、薬学雑誌、130、1527-1534 (2010)
水口裕之；次世代アデノウイルスベクターの開発と生命科学研究への応用、Drug Delivery System、25, 493-503 (2010)
